NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said Saturday that the company and the U.S. Department of Health & Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development.
As per the agreement, the company's Janssen will commit about $604 million and the U.S. Department of Health & Human Services' the Biomedical Advanced Research and Development Authority or BARDA will commit about $454 million to support the ongoing Phase 3 ENSEMBLE trial.
The trial is evaluating Janssen's investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.
Copyright RTT News/dpa-AFX